RT-102

Peptide

DiscontinuedPTH1 receptorNo recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued, as a strategic decision by the sponsor

Rani's FY2025 10-K: in 2026, as part of a strategic prioritization of its pipeline, Rani discontinued RT-102 (osteoporosis) and RT-110. Rani keeps the rights, may explore partnerships, and has no current plans to resume development. No exact date is stated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Featured evidence outside this drug's tracked markets:NCT05164614 · Healthy Volunteers · Phase 1 · completed · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT05164614 · RANI Therapeutics
2022-02-21 – 2022-10-17 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Osteoporosis: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RT-102: this drugDiscontinuedPeptidePTH1 receptornot yet gradedNo reviewed efficacy summary in this indication
Denosumab (Prolia)ApprovedMonoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic Acid (Reclast)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.